WO2012097471A1 - PREPARATION METHOD OF β-METHYL CARBAPENEM COMPOUND - Google Patents
PREPARATION METHOD OF β-METHYL CARBAPENEM COMPOUND Download PDFInfo
- Publication number
- WO2012097471A1 WO2012097471A1 PCT/CN2011/000076 CN2011000076W WO2012097471A1 WO 2012097471 A1 WO2012097471 A1 WO 2012097471A1 CN 2011000076 W CN2011000076 W CN 2011000076W WO 2012097471 A1 WO2012097471 A1 WO 2012097471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- formula
- hydrazine
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/18—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
Definitions
- the present invention relates to a method for preparing a ⁇ -mercaptocarbamene compound, and in particular,
- a compound of the formula (I), ie (4R,5S,6S)-3-[[(3S,5S)-5-(didecylaminocarbonyl)-3-pyrrolidinyl]thio]-6- [(1R)-1-Hydroxyethyl]-4-indolyl-7-oxo-1-azabicyclo[3.2. 0]hept-2-en-2-indoleic acid trihydrate is an antibiotic in the pharmaceutical industry An important raw material for production.
- Cisokakukanesuene discloses a process for preparing a compound of the formula (I): a compound of the formula (III) is reacted with a compound of the formula (IV) in the presence of a base to synthesize a compound of the formula (II).
- reaction solution containing the compound of the formula ( ⁇ ) is subjected to extraction/brine washing/water washing to obtain a water-saturated ethyl acetate solution containing the compound of the formula ( ⁇ ).
- a palladium carbon catalyst is added to carry out a hydrodeprotection reaction, and after completion of the reaction, palladium carbon is removed by filtration, and the reaction liquid containing the compound represented by the formula (I) is used.
- reaction liquid of the compound of the formula (II) is subjected to a series of post-treatment processes such as extraction, washing with water, washing with water, etc.; the obtained reaction liquid containing the compound of the formula (I) is also required.
- a series of post-treatment processes such as pH adjustment of acid, concentration under reduced pressure, addition of activated carbon and filtration, resulting in cumbersome steps, increased cost, increased raw material loss and increased environmental pollution, are not conducive to industrial production in the pharmaceutical industry and environmental protection.
- the substituent of the substituted carbonyl group, sulfonyl group or phosphoryl group is an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aromatic group, a heterocyclic group, An amino group, an aliphatic alkoxy group, an aromatic oxy group, an aliphatic hydrocarbon group substituted with an aryl group or a heterocyclic group or an amino group substituted with an aryl group or a heterocyclic group;
- the compound is selected from alkanoyl groups having 1 to 6 carbon atoms, such as decanoyl group, acetyl group, propionyl group, butyryl group, valeryl group and hexanoyl group; acryloyl group; having 1 to 6 carbon atoms
- alkylsulfonyl group such as a sulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, a butylsulfonyl group, a pentylsulfonyl group and a hexylsulfonyl group
- an alkoxycarbonyl group having 1 to 5 carbon atoms such as a decanoyl group, an ethoxylated group, Propoxyl, butanoyl and valeryl
- propyleneoxycarbonyl with 1 Alkoxyphosphoryl group of up to 5 carbon atoms, such as diethoxyphosphor,
- R is a diphenoxyphosphoryl group.
- the base may be an organic base such as a trialkylamine, a tridecylamine, a triethylamine, a tributylamine, a triamylamine, a trihexylamine, a trioctylamine, and an anthracene.
- organic base such as a trialkylamine, a tridecylamine, a triethylamine, a tributylamine, a triamylamine, a trihexylamine, a trioctylamine, and an anthracene.
- ⁇ -diisopropylethylamine dialkylamine, hydrazine, hydrazine-diisopropylamine; pyridine; pyridine having a substituent on the pyridine ring, such as 2,6-dimercaptopyridine, 3,5- Dimercaptopyridine, 2,3,5-tridecylpyridine, 2,4,6-trimercaptopyridine, 3-mercaptopyridine, 2-mercaptopyridine and 4-methylpyridine; quinoline; An alkylmorpholine; and one or more of tetrakisinium, preferably ruthenium, osmium-diisopropylethylamine, hydrazine, hydrazine-diisopropylamine or tetradecyl hydrazine;
- the organic solvent is selected from the group consisting of: fluorene-fluorenylpyrrolidone, hydrazine-ethylpyrrolidone; hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-dimercaptoacetamide; nitrile, such as acetonitrile; halogenated hydrocarbon, such as two Chlorodecane, chloroform and carbon tetrachloride; aromatic hydrocarbons such as toluene; ketones, acetone and butanone; tetrahydrofuran; oxime, ethyl acetate and decyl acetate; alcohols such as decyl alcohol, ethanol, n-propanol and One or more of isopropanol, preferably dichlorodecane, tetrahydrofuran, acetonitrile, ethyl acetate, hydrazine,
- the aqueous acid solution is selected from the group consisting of inorganic acids such as hydrochloric acid, acid, nitric acid, phosphoric acid, potassium dihydrogen phosphate, and sodium dihydrogen phosphate; and organic acids such as one or more of citric acid, acetic acid, sulfonic acid, and trifluoroacetic acid.
- inorganic acids such as hydrochloric acid, acid, nitric acid, phosphoric acid, potassium dihydrogen phosphate, and sodium dihydrogen phosphate
- organic acids such as one or more of citric acid, acetic acid, sulfonic acid, and trifluoroacetic acid.
- Sodium dihydrogen phosphate is preferred.
- the molar ratio of the compound of the formula (IV) to the compound of the formula (III) is 1: 0.8-3.0, preferably 1: 1.0-1.5 mol; the base and the formula (III)
- the molar ratio of the compound is 1: 0.8 to 5.0 moles, preferably 1: 1.0 to 3.0 moles;
- the temperature of the reaction is -50 ° C to 5 (TC, preferably -30 ° C to 3 (TC;
- the mass ratio of the organic solvent to the compound of the formula (III) is from 1 to 40:1, preferably from 2 to 20:1;
- the volume ratio of the aqueous acid solution to the reaction product is 1: 0.1-20, preferably 1 : 0.5-10;
- the concentration of the aqueous acid solution is 0.01 mol / liter to 10 mol / liter, preferably 0.01 mol / liter ⁇ 5 mol / liter;
- the washing temperature is 0 ° C ⁇ 40 ° C, It is preferably 20
- step (A) adding a water-immiscible organic solvent, preferably a hydrocarbon, such as dichlorosilane and chloroform, when separating the organic solution layer containing the compound of the formula (II); Esters such as ethyl acetate and methyl acetate; hydrocarbons such as petroleum ether and n-pentane; aromatic hydrocarbons such as toluene; alcohols such as n-butanol and n-pentanol; ketones such as 2-butanone and 2-pentanone; Ether, such as B One or more of the ethers.
- a water-immiscible organic solvent preferably a hydrocarbon, such as dichlorosilane and chloroform
- the organic solution containing the compound of the formula (II) is concentrated before the reaction, or water and/or one or more is added to the organic solution containing the compound of the formula ( ⁇ ) before the reaction.
- the base is selected from an organic base such as pyridine; a pyridine having a substituent on the pyridine ring, such as 2,6-dimercaptopyridine, 3,5-dimercaptopyridine, 2, 3,5-trimercaptopyridine, 2,4,6-trimercaptopyridine, 3-mercaptopyridine, 2-mercaptopyridine and 4-mercaptopyridine; morpholine; quinoline; pyrimidine; 4-di Aminopyridine; triethylamine, diethylamine, tributylamine, diisopropylethylamine and diisopropylamine; inorganic bases such as disodium hydrogen phosphate, dipotassium hydrogen phosphate; one of sodium carbonate and potassium carbonate One or more; the catalyst is a catalyst containing palladium and/or platinum, preferably a palladium-containing catalyst, more preferably a palladium catalyst supported on activated carbon; the solvent of the crystallization is selected from a
- the pressure of the hydrogen gas is 0.05 to 6.0 MPa, preferably 0.1 to 4.0 MPa; the temperature of the reaction is 0 to 70 ° C, preferably 15 to 50 ° C; the solvent of the crystallization
- the volume ratio to the reaction product is from 0.2 to 50:1, preferably from 1 to 10:1.
- step (B) a seed crystal is added during the crystallization; the crystallization is stirred or not stirred.
- reaction solution containing the compound of the formula (II) obtained by reacting the compound of the formula (III) with the compound of the formula (IV) needs to be washed only one to ten times with an aqueous solution containing an acid. It is preferably five times and can be used in the next reaction without additional post-treatment, which would otherwise affect the product quality and yield of the subsequent reaction product, ie, the compound of formula (I).
- the reaction solution containing the compound of the formula (II) subjected to the treatment is concentrated, and water, an organic solvent, a base, a noble metal catalyst is added, and hydrogen is deprotected in an autoclave to obtain a compound containing the compound of the formula (I).
- the reaction solution is filtered to remove the catalyst, and the reaction liquid at this time is directly added to the crystallizing solvent without further post-treatment, whereby a compound of the formula (I) having a good yield and high quality can be obtained.
- Example 1 The present invention is further described in detail with reference to the preferred embodiments of the present invention.
- Example 1 The present invention is further described in detail with reference to the preferred embodiments of the present invention.
- the starting compound Ilia was obtained by the method disclosed in Chinese Patent ZL200610057578.6. Unless otherwise stated, other test materials are commercially available.
- the compound of the formula (I) was prepared by a method similar to that of Example 1 and Example 2, except that the following two methods were used in the post-treatment of the compound of the intermediate formula ( ⁇ ):
- Method 1 Wash once with water, twice with saline, and then once with water;
- Method 2 Wash five times with an aqueous solution of potassium dihydrogen phosphate (KH 2 P0 4 ).
- the yields of the products obtained by the methods 1 and 2 were significantly different.
- the compound of the formula (I) was prepared by a method similar to that of Example 1 and Example 2, except that the method of the intermediate formula ( ⁇ ) was used in the post-treatment of the compound (Method 1) and Method 2, respectively. Two batches of experiments were carried out, and a batch of experiments were carried out in accordance with Method 2 for comparison. The results are shown in Table 1.
- the method 2 for preparing the compound of the formula (II) by using the compound of the formula (III) can be used to make the organic solution system containing the compound of the formula (II) relatively pure, thereby making the formula ( ⁇ )
- the compound shown in the preparation of the compound of the formula (I) can be obtained by direct crystallization after completion of the reaction, and the purity and yield are higher; and if the compound of the formula (III) is used to prepare the formula (II) In the reaction solution of the compound, the method 2 is used, that is, washing with a saline solution.
- the emulsification phenomenon is likely to occur during the post-treatment, which causes a decrease in the yield loss and purity of the compound represented by the formula (II) in the product solution; If the direct crystallization method according to the present invention is carried out in the preparation of the compound of the formula (I) in the compound of the formula (II), the purity of the product of the compound of the formula (I) obtained is affected, and cumbersome post-treatment must be employed. The method is to obtain a product with higher purity, and the yield thereof is greatly reduced.
- the compound of the formula (I) was prepared by a method similar to that of Example 1 and Example 2, except that the solution shown in Table 2 was used for the post-treatment of the compound of the formula (II), and the results were as follows. Table 2 shows. Table 2 Effect of different kinds of washing solutions on product yield and yield
- the compound of the formula (?) was prepared in the same manner as in Example 1, except that the washing was carried out by the washing temperature shown in Table 3 in the post-treatment, and the results are shown in Table 3.
- Table 3 Effect of Different Washing Temperatures on Product Yield
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
Abstract
Description
β-甲基碳青霉烯化合物的制备方法 技术领域 Method for preparing β-methyl carbapenem compound
本发明涉及一种 β-曱基碳青霉烯化合物的制备方法, 具体来说, 涉及 The present invention relates to a method for preparing a β-mercaptocarbamene compound, and in particular,
(4R,5S,6S) -3-[[(3S,5S)-5- (二曱基氨基羰基) -3-吡咯烷基]硫基] -6-[ ( 1R)小 羟乙基 ]-4-曱基 -7-氧代 - 1 -氮杂汉环 [3.2.0]庚 -2-烯 -2-曱酸三水合物的制备方 法。 背景技术 (4R,5S,6S) -3-[[(3S,5S)-5-(didecylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1R)hydroxyethyl]- A process for the preparation of 4-mercapto-7-oxo- 1 -azahan ring [3.2.0]hept-2-en-2-indole acid trihydrate. Background technique
通式 (I) 所示化合物, 即 (4R,5S,6S) -3-[[(3S,5S)-5- (二曱基氨基羰 基) -3-吡咯烷基]硫基] -6-[ ( 1R) -1-羟乙基 ]-4-曱基 -7-氧代 -1-氮杂双环 [3.2. 0]庚 -2-烯 -2-曱酸三水合物是制药工业中抗生素生产的重要原料。 中国发明 专利申请 CN101410398A公开了式 (I) 所示化合物的制备方法: 在碱存 在下, 式(III) 所示化合物与式 (IV) 所示化合物反应, 合成式 (II) 所 示化合物。 A compound of the formula (I), ie (4R,5S,6S)-3-[[(3S,5S)-5-(didecylaminocarbonyl)-3-pyrrolidinyl]thio]-6- [(1R)-1-Hydroxyethyl]-4-indolyl-7-oxo-1-azabicyclo[3.2. 0]hept-2-en-2-indoleic acid trihydrate is an antibiotic in the pharmaceutical industry An important raw material for production. Chinese Patent Application CN101410398A discloses a process for preparing a compound of the formula (I): a compound of the formula (III) is reacted with a compound of the formula (IV) in the presence of a base to synthesize a compound of the formula (II).
(II) (II)
(III) (IV) 将含有式(Π)所示化合物的反应液进行萃取 /食盐水洗涤 /水洗涤, 得 到含有式(Π)所示化合物的水饱和乙酸乙酯溶液。 向含有式(Π)所示化 合物的水饱和乙酸乙酯溶液中加入钯碳催化剂, 进行加氢脱保护反应, 反 应完毕后过滤除去钯碳, 将含有式(I)所示化合物的反应液用酸调节 pH/ 减压浓缩 /加入活性炭搅拌 /过滤 /加入溶剂结晶。 在上述制备方法中, 中间 体式 (II) 所示化合物的反应液需要进行萃取、 食盐水洗涤、 水洗涤等一 系列后处理过程; 得到的含有式(I)所示化合物的反应液同样需要用酸调 节 pH、 减压浓缩、 加入活性炭搅拌和过滤等一系列后处理过程, 导致该 制备方法步骤繁瑣、 成本增加、 原料损耗增加和环境污染加剧, 不利于制 药行业的工业化生产和日益重视的环保要求。 发明内容 (III) (IV) The reaction solution containing the compound of the formula (Π) is subjected to extraction/brine washing/water washing to obtain a water-saturated ethyl acetate solution containing the compound of the formula (Π). To a water-saturated ethyl acetate solution containing a compound of the formula (Π), a palladium carbon catalyst is added to carry out a hydrodeprotection reaction, and after completion of the reaction, palladium carbon is removed by filtration, and the reaction liquid containing the compound represented by the formula (I) is used. Acid adjustment pH / concentration under reduced pressure / addition of activated carbon stirring / filtration / addition of solvent crystallization. In the above preparation method, the reaction liquid of the compound of the formula (II) is subjected to a series of post-treatment processes such as extraction, washing with water, washing with water, etc.; the obtained reaction liquid containing the compound of the formula (I) is also required. A series of post-treatment processes such as pH adjustment of acid, concentration under reduced pressure, addition of activated carbon and filtration, resulting in cumbersome steps, increased cost, increased raw material loss and increased environmental pollution, are not conducive to industrial production in the pharmaceutical industry and environmental protection. Claim. Summary of the invention
因此, 本发明的目的是寻找一种操作简洁、 环保且可大规模工业化制 备式(I) 所示化合物的方法。 Accordingly, it is an object of the present invention to find a process which is simple, environmentally friendly and can be industrially produced on a large scale to produce a compound of the formula (I).
用于实现上述目的的技术方案如下: The technical solution for achieving the above object is as follows:
一种式 (I) 所示化合物的制备方法, 该制备方法包括以下步骤: A method for preparing a compound of the formula (I), which comprises the steps of:
(A)将式 (III) 所示化合物与式(IV)所示化合物在碱存在下于有 机溶剂中反应生成式 (II) 所示化合物, 使用酸的水溶液洗涤反应产物并 分离出含有式 (II) 所示化合物的有机溶液层; (A) reacting a compound of the formula (III) with a compound of the formula (IV) in an organic solvent in the presence of a base to form a compound of the formula (II), washing the reaction product with an aqueous acid solution and isolating the formula ( II) an organic solution layer of the compound shown;
(B)向含有式(II)所示化合物的有机溶液中加入碱、 催化剂和氢气 进行反应后结晶生成式 (I) 所示化合物。 (B) A reaction is carried out by adding a base, a catalyst and hydrogen to an organic solution containing the compound of the formula (II), followed by crystallization to give a compound of the formula (I).
( I ) 其中, !^为酰基。 ( I ) Among them, ! ^ is an acyl group.
具体来说 可以为未取代或取代的碳酰基、 磺酰基或磷酰基; 优选地, 取代的碳酰基、 磺酰基或磷酰基的取代基为脂肪烃基、 脂环 烃基、 芳香基、 杂环基、 氨基、 脂肪烃氧基、 芳香氧基、 被芳香基或杂环 基取代的脂肪烃基或者被芳香基或杂环基取代的氨基; Specifically, it may be an unsubstituted or substituted carbonyl group, a sulfonyl group or a phosphoryl group; preferably, the substituent of the substituted carbonyl group, sulfonyl group or phosphoryl group is an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aromatic group, a heterocyclic group, An amino group, an aliphatic alkoxy group, an aromatic oxy group, an aliphatic hydrocarbon group substituted with an aryl group or a heterocyclic group or an amino group substituted with an aryl group or a heterocyclic group;
进一步优选地, 所述 1^选自具有 1至 6个碳原子的烷酰基, 例如曱 酰基、 乙酰基、 丙酰基、 丁酰基、 戊酰基和己酰基; 丙烯酰基; 具有 1至 6个碳原子的烷基磺酰基, 例如曱磺酰基、 乙磺酰基、 丙磺酰基、 丁磺酰 基、 戊磺酰基和己磺酰基; 具有 1至 5个碳原子的烷氧酰基, 例如曱氧酰 基、 乙氧酰基、 丙氧酰基、 丁氧酰基和戊样酰基; 丙烯氧基羰基; 具有 1 至 5个碳原子的烷氧磷酰基, 例如二乙氧基磷酰基; 苯酰基; 苯磺酰基, 例如对曱苯磺酰基; 苯磷酰基; 苯氧磷酰基, 例如二苯氧磷酰基; 苯基氨 基酰基, N-苯基氨基曱酰基; 呋喃曱酰基; 噻唑基羰基; 苯基乙酰基; 苯 基丙酰基; 苄氧羰基; 咪唑基乙酰基; Further preferably, the compound is selected from alkanoyl groups having 1 to 6 carbon atoms, such as decanoyl group, acetyl group, propionyl group, butyryl group, valeryl group and hexanoyl group; acryloyl group; having 1 to 6 carbon atoms An alkylsulfonyl group such as a sulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, a butylsulfonyl group, a pentylsulfonyl group and a hexylsulfonyl group; an alkoxycarbonyl group having 1 to 5 carbon atoms, such as a decanoyl group, an ethoxylated group, Propoxyl, butanoyl and valeryl; propyleneoxycarbonyl; with 1 Alkoxyphosphoryl group of up to 5 carbon atoms, such as diethoxyphosphoryl; benzoyl; phenylsulfonyl, for example p-toluenesulfonyl; phenylphosphoryl; phenoxyphosphoryl, such as diphenoxyphosphoryl; Aminoamino group, N-phenylaminodecanoyl; furanoyl; thiazolylcarbonyl; phenylacetyl; phenylpropionyl; benzyloxycarbonyl; imidazolylacetyl;
更优选地, 为二芳氧基磷酰基; More preferably, it is a diaryloxyphosphoryl group;
最优选地, R,为二苯氧基磷酰基。 Most preferably, R is a diphenoxyphosphoryl group.
在所述步骤 (A ) 中, 所述碱可以为有机碱, 例如三烷基胺, 三曱基 胺、 三乙胺、 三丁胺、 三戊胺、 三己胺、 三辛胺和 Ν,Ν-二异丙基乙基胺; 二烷基胺, Ν,Ν-二异丙基胺; 吡啶; 吡啶环上具有取代基的吡啶,例如 2,6- 二曱基吡啶、 3,5-二曱基吡啶、 2,3,5-三曱基吡啶、 2,4,6-三曱基吡啶、 3- 曱基吡啶、 2-曱基吡啶和 4-甲基吡啶; 喹啉; Ν-烷基吗啉; 以及四曱基胍 中的一种或多种,优选为 Ν,Ν-二异丙基乙基胺、 Ν,Ν-二异丙基胺或四曱基 胍; In the step (A), the base may be an organic base such as a trialkylamine, a tridecylamine, a triethylamine, a tributylamine, a triamylamine, a trihexylamine, a trioctylamine, and an anthracene. Ν-diisopropylethylamine; dialkylamine, hydrazine, hydrazine-diisopropylamine; pyridine; pyridine having a substituent on the pyridine ring, such as 2,6-dimercaptopyridine, 3,5- Dimercaptopyridine, 2,3,5-tridecylpyridine, 2,4,6-trimercaptopyridine, 3-mercaptopyridine, 2-mercaptopyridine and 4-methylpyridine; quinoline; An alkylmorpholine; and one or more of tetrakisinium, preferably ruthenium, osmium-diisopropylethylamine, hydrazine, hydrazine-diisopropylamine or tetradecyl hydrazine;
所述有机溶剂选自: Ν-曱基吡咯烷酮、 Ν-乙基吡咯烷酮; Ν,Ν-二曱基 曱酰胺、 Ν,Ν-二曱基乙酰胺; 腈, 例如乙腈; 卤代烃, 例如二氯曱烷、 三 氯甲烷和四氯化碳; 芳香烃, 例如甲苯; 酮, 丙酮和丁酮; 四氢呋喃; 酉旨, 乙酸乙酯和乙酸曱酯; 醇, 例如曱醇、 乙醇、 正丙醇和异丙醇中的一种或 多种, 优选为二氯曱烷、 四氢呋喃、 乙腈、 乙酸乙酯、 Ν,Ν-二曱基曱酰胺、 Ν,Ν-二曱基乙酰胺、 Ν-曱基吡咯烷酮、 Ν-乙基吡咯烷酮和曱苯中的一种或 多种; The organic solvent is selected from the group consisting of: fluorene-fluorenylpyrrolidone, hydrazine-ethylpyrrolidone; hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-dimercaptoacetamide; nitrile, such as acetonitrile; halogenated hydrocarbon, such as two Chlorodecane, chloroform and carbon tetrachloride; aromatic hydrocarbons such as toluene; ketones, acetone and butanone; tetrahydrofuran; oxime, ethyl acetate and decyl acetate; alcohols such as decyl alcohol, ethanol, n-propanol and One or more of isopropanol, preferably dichlorodecane, tetrahydrofuran, acetonitrile, ethyl acetate, hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-dimercaptoacetamide, hydrazine-fluorenyl One or more of pyrrolidone, hydrazine-ethylpyrrolidone and toluene;
所述酸的水溶液选自无机酸, 例如盐酸、 酸、 硝酸、 磷酸、 磷酸二 氢钾和磷酸二氢钠; 有机酸, 例如曱酸、 乙酸、 磺酸和三氟乙酸中的一种 或多种的水溶液。 优选磷酸二氢钠。 The aqueous acid solution is selected from the group consisting of inorganic acids such as hydrochloric acid, acid, nitric acid, phosphoric acid, potassium dihydrogen phosphate, and sodium dihydrogen phosphate; and organic acids such as one or more of citric acid, acetic acid, sulfonic acid, and trifluoroacetic acid. Kind of aqueous solution. Sodium dihydrogen phosphate is preferred.
在所述步骤 (Α ) 中, 所述式 (IV )化合物与式 (III )化合物的摩尔 比为 1 : 0.8-3.0, 优选为 1 : 1.0〜1.5摩尔; 所述碱与式( III ) 所示化合物 的摩尔比为 1 : 0.8〜5.0摩尔, 优选为 1 : 1.0~3.0摩尔; 所述反应的温度为 -50°C〜5(TC, 优选为 -30°C~3(TC ; 所述有机溶剂与所述式 (III ) 所示化合 物的质量比为 1〜40: 1 , 优选为 2~20: 1 ; 所述酸的水溶液与反应产物的 体积比为 1 : 0.1-20, 优选为 1 : 0.5-10; 所述酸的水溶液的浓度为 0.01 摩尔 /升〜 10摩尔 /升, 优选为 0.01摩尔 /升〜 5摩尔 /升; 所述洗涤的温度为 0 °C〜40°C, 优选为 20°C〜40°C , 更优选为 34°C。 In the step (Α), the molar ratio of the compound of the formula (IV) to the compound of the formula (III) is 1: 0.8-3.0, preferably 1: 1.0-1.5 mol; the base and the formula (III) The molar ratio of the compound is 1: 0.8 to 5.0 moles, preferably 1: 1.0 to 3.0 moles; the temperature of the reaction is -50 ° C to 5 (TC, preferably -30 ° C to 3 (TC; The mass ratio of the organic solvent to the compound of the formula (III) is from 1 to 40:1, preferably from 2 to 20:1; the volume ratio of the aqueous acid solution to the reaction product is 1: 0.1-20, preferably 1 : 0.5-10; the concentration of the aqueous acid solution is 0.01 mol / liter to 10 mol / liter, preferably 0.01 mol / liter ~ 5 mol / liter; the washing temperature is 0 ° C ~ 40 ° C, It is preferably 20 ° C to 40 ° C, more preferably 34 ° C.
在所述步骤(A ) 中, 在分离出含有式(II )所示化合物的有机溶液层 时加入与水不混溶的有机溶剂,优选为 代烃,例如二氯曱烷和三氯甲烷; 酯, 例如乙酸乙酯和乙酸甲酯; 烃, 例如石油醚和正戊烷; 芳香烃, 例如 曱苯; 醇, 例如正丁醇和正戊醇; 酮, 例如 2-丁酮和 2-戊酮; 醚, 例如乙 醚中的一种或多种。 In the step (A), adding a water-immiscible organic solvent, preferably a hydrocarbon, such as dichlorosilane and chloroform, when separating the organic solution layer containing the compound of the formula (II); Esters such as ethyl acetate and methyl acetate; hydrocarbons such as petroleum ether and n-pentane; aromatic hydrocarbons such as toluene; alcohols such as n-butanol and n-pentanol; ketones such as 2-butanone and 2-pentanone; Ether, such as B One or more of the ethers.
在所述步骤(B ) 中, 反应前将含有式(II )所示化合物的有机溶液浓 缩, 或者反应前向含有式(Π ) 所示化合物的有机溶液加入水和 /或一种或 多种选自 N-曱基吡咯烷酮、 N-乙基吡咯烷酮; N,N-二曱基曱酰胺、 N,N- 二曱基乙酰胺; 腈, 例如乙腈; 1¾代烃, 例如二氯曱烷、 三氯曱烷和四氯 化碳; 芳香烃, 例如曱苯; 酮, 例如丙酮和丁酮; 四氢呋喃; 酯, 乙酸乙 酯和乙酸曱酯; 醇, 曱醇、 乙醇、 正丙醇和异丙醇, 优选为二氯曱烷、 四 氢呋喃、 乙腈、 乙酸乙酯、 Ν,Ν-二曱基曱酰胺、 Ν,Ν-二曱基乙酰胺、 Ν- 甲基吡咯烷酮、 Ν-乙基吡咯烷酮和曱苯中的一种或多种的有机溶剂。 In the step (B), the organic solution containing the compound of the formula (II) is concentrated before the reaction, or water and/or one or more is added to the organic solution containing the compound of the formula (Π) before the reaction. Selected from N-decyl pyrrolidone, N-ethylpyrrolidone; N,N-dimercaptoamide, N,N-dimercaptoacetamide; nitrile, such as acetonitrile; 13⁄4 hydrocarbon, such as dichlorodecane, three Chlorodecane and carbon tetrachloride; aromatic hydrocarbons such as toluene; ketones such as acetone and methyl ethyl ketone; tetrahydrofuran; esters, ethyl acetate and decyl acetate; alcohols, sterols, ethanol, n-propanol and isopropanol, Preferred are dichlorodecane, tetrahydrofuran, acetonitrile, ethyl acetate, hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-dimercaptoacetamide, hydrazine-methylpyrrolidone, hydrazine-ethylpyrrolidone and toluene. One or more organic solvents.
在所述步骤 (Β ) 中, 所述碱选自有机碱, 例如吡啶; 吡啶环上具有 取代基的吡啶, 例如 2,6-二曱基吡啶、 3,5-二曱基吡啶、 2,3,5-三曱基吡啶、 2,4,6-三曱基吡啶、 3-曱基吡啶、 2-曱基吡啶和 4-曱基吡啶; 吗啉; 喹啉; 嘧啶; 4-二曱氨基吡啶; 三乙胺、 二乙胺、 三丁胺、 二异丙基乙胺和二异 丙基胺; 无机碱, 例如磷酸氢二钠、 磷酸氢二钾; 碳酸鈉和碳酸钾中的一 种或多种; 所述催化剂为含钯和 /或铂的催化剂, 优选为含钯的催化剂, 更 优选负载于活性炭上的钯催化剂; 所述结晶的溶剂选自腈, 例如乙腈; 卤 代烃, 例如二氯曱烷; 芳香烃, 例如曱苯; 酮, 例如丙酮和丁酮; 四氢呋 喃; 酯, 乙酸乙酯和乙酸曱酯; 醇, 例如曱醇、 乙醇、 正丙醇和异丙醇中 的一种或多种, 优选为二氯曱烷、 四氢呋喃、 乙腈、 丙酮和甲醇中的一种 或多种。 In the step (Β), the base is selected from an organic base such as pyridine; a pyridine having a substituent on the pyridine ring, such as 2,6-dimercaptopyridine, 3,5-dimercaptopyridine, 2, 3,5-trimercaptopyridine, 2,4,6-trimercaptopyridine, 3-mercaptopyridine, 2-mercaptopyridine and 4-mercaptopyridine; morpholine; quinoline; pyrimidine; 4-di Aminopyridine; triethylamine, diethylamine, tributylamine, diisopropylethylamine and diisopropylamine; inorganic bases such as disodium hydrogen phosphate, dipotassium hydrogen phosphate; one of sodium carbonate and potassium carbonate One or more; the catalyst is a catalyst containing palladium and/or platinum, preferably a palladium-containing catalyst, more preferably a palladium catalyst supported on activated carbon; the solvent of the crystallization is selected from a nitrile such as acetonitrile; For example, dichloromethane; aromatic hydrocarbons such as toluene; ketones such as acetone and methyl ethyl ketone; tetrahydrofuran; esters, ethyl acetate and decyl acetate; alcohols such as decyl alcohol, ethanol, n-propanol and isopropanol One or more, preferably dichlorosilane, tetrahydrofuran, acetonitrile, acetone and methanol One or more.
在所述步骤(Β )中,氢气的压力为 0.05〜6.0MPa,优选为 0.1〜4.0 MPa; 所述反应的温度为 0~70°C, 优选为 15~50°C ; 所述结晶的溶剂与反应产物 的体积比为 0.2〜50: 1 , 优选为 1〜10: 1。 In the step (Β), the pressure of the hydrogen gas is 0.05 to 6.0 MPa, preferably 0.1 to 4.0 MPa; the temperature of the reaction is 0 to 70 ° C, preferably 15 to 50 ° C; the solvent of the crystallization The volume ratio to the reaction product is from 0.2 to 50:1, preferably from 1 to 10:1.
在所述步骤(B ) 中, 所述结晶时添加晶种; 所述结晶过程中搅拌或 不搅拌。 In the step (B), a seed crystal is added during the crystallization; the crystallization is stirred or not stirred.
本发明人通过大量研究发现, 式(III )所示化合物与式(IV )所示化 合物反应获得的含有式 (II ) 所示化合物的反应液仅需用含酸的水溶液洗 涤一到十次, 优选为五次, 无需进行另外的后处理即可以用于下一步的反 应, 否则会影响到后续反应产品, 即式(I )所示化合物的产品质量和收率。 而将经过该种处理的含有式 (II )所示化合物的反应液浓缩, 加入水、 有 机溶剂、 碱、 贵金属催化剂, 在高压釜中通入氢气脱保护得到含有式(I ) 所示化合物的反应液, 过滤除去催化剂, 此时的反应液无需进行其它后处 理, 直接加入结晶溶剂结晶, 即可以得到收率良好、 高品质的式(I )所示 化合物。 实施发明的最佳方式 The inventors have found through extensive studies that the reaction solution containing the compound of the formula (II) obtained by reacting the compound of the formula (III) with the compound of the formula (IV) needs to be washed only one to ten times with an aqueous solution containing an acid. It is preferably five times and can be used in the next reaction without additional post-treatment, which would otherwise affect the product quality and yield of the subsequent reaction product, ie, the compound of formula (I). The reaction solution containing the compound of the formula (II) subjected to the treatment is concentrated, and water, an organic solvent, a base, a noble metal catalyst is added, and hydrogen is deprotected in an autoclave to obtain a compound containing the compound of the formula (I). The reaction solution is filtered to remove the catalyst, and the reaction liquid at this time is directly added to the crystallizing solvent without further post-treatment, whereby a compound of the formula (I) having a good yield and high quality can be obtained. The best way to implement the invention
下面结合具体实施方式对本发明进行进一步的详细描述,给出的实施例 仅为了阐明本发明, 而不是为了限制本发明的范围。 实施例 1 The present invention is further described in detail with reference to the preferred embodiments of the present invention. Example 1
起始化合物 Ilia是按照中国专利 ZL200610057578.6公开的方法制备获 得。 如无特别说明, 其它试验材料均为市售。 The starting compound Ilia was obtained by the method disclosed in Chinese Patent ZL200610057578.6. Unless otherwise stated, other test materials are commercially available.
化合物 (4R,5S,6S ) -3-[[(3S,5S)-l- (对硝基苄氧羰基) -5- (二曱基氨基 羰基) -3-吡咯烷基]硫基] -6-[ ( 1R ) -1-羟乙基 ]-4-曱基 -7-氧代 -1-氮杂双环 [3.2. Compound (4R,5S,6S)-3-[[(3S,5S)-l-(p-Nitrobenzyloxycarbonyl)-5-(didecylaminocarbonyl)-3-pyrrolidinyl]thio] 6-[ ( 1R ) -1-Hydroxyethyl]-4-indolyl-7-oxo-1-azabicyclo[3.2.
( Π) ( Π)
将 33.0g的化合物 ( 4R,5R,6S ) -3-二苯氧基磷酰氧基 -6-[ ( 1R ) -1-羟 乙基] -4-曱基 -7-氧代 -1-氮杂双环 [3.2.0]庚 -2-烯 -2-曱酸对硝基苄酯(Ilia )加 入到反应瓶中, 加入 200.0g乙腈、 lO.Og二异丙基乙胺, 19.0g式 IV所示化 合物, 在 -10°C下反应。 反应完毕, 向反应液中补加 500g乙酸乙酯, 用 500 毫升的 6% ( g/mL )磷酸二氢钠水溶液洗涤两次, 洗涤温度为 34°C , 分相, 得到含有式 II所示化合物的有机溶液。 实施例 2 33.0 g of the compound ( 4R,5R,6S )-3-diphenoxyphosphoryloxy-6-[(1R)-1-hydroxyethyl]-4-indolyl-7-oxo-1- Azabicyclo[3.2.0]hept-2-ene-2-decanoic acid p-nitrobenzyl ester (Ilia) was added to the reaction flask, and 200.0 g of acetonitrile, 10.Og of diisopropylethylamine, 19.0 g of the formula was added. The compound shown in IV was reacted at -10 °C. After completion of the reaction, 500 g of ethyl acetate was added to the reaction solution, and washed twice with 500 ml of a 6% (g/mL) aqueous solution of sodium dihydrogen phosphate, and the washing temperature was 34 ° C, and the phases were separated to obtain the formula II. An organic solution of the compound. Example 2
( 4R, 5S, 6S ) -3-[[(3S, 5S)-5- (二曱基氨基羰基) -3-吡咯烷基]硫 基] -6-[ ( 1R ) -1-羟乙基 ]-4-曱基 -7-氧代 -1-氮杂双环 [3.2.0]庚 -2-烯 -2-曱酸三 水合物 (I ) 的制备 ( 4R, 5S, 6S ) -3-[[(3S, 5S)-5-(didecylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl Preparation of 4-mercapto-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-decanoic acid trihydrate (I)
( π) ( I) 将实施例 1中获得的含有化合物(II )(即(4R,5S,6S)-3-[[(3S,5S)-l- (对 硝基苄氧羰基 )-5- (二曱基氨基羰基) -3-吡咯烷基]硫基] -6-[ ( 1R)小羟乙 基] -4-曱基 -7-氧代 -1-氮杂双环 [3.2.0]庚 -2-烯 -2-曱酸对硝基苄酯) 的有机溶 液浓缩, 浓缩液导入到高压釜中, 补加 600g的四氢呋喃, 加入 20g的钯 碳催化剂 3.5g的二曱基吡啶, 导入氢气, 压力至 0.5MPa左右, 温度控制 在 0~50°C反应,反应完毕,过滤除去钯碳等催化剂,滤液转入到结晶瓶中, 加入 1000g的丙酮,于 0°C左右搅拌结晶。过滤,得到 18.2g的化合物(1)。 (π) (I) The compound (II) obtained in Example 1 (i.e., (4R, 5S, 6S)-3-[[(3S,5S)-l-(p-nitrobenzyloxycarbonyl)-5) - (didecylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1R)hydroxyethyl]-4-indolyl-7-oxo-1-azabicyclo[3.2.0 The organic solution of p-nitro-2-ene-2-nonanoic acid p-nitrobenzyl ester was concentrated, and the concentrate was introduced into an autoclave, 600 g of tetrahydrofuran was added, and 20 g of palladium carbon catalyst was added to 3.5 g of dimercaptopyridine. Hydrogen was introduced, the pressure was about 0.5 MPa, and the temperature was controlled at 0 to 50 ° C. After the reaction was completed, a catalyst such as palladium carbon was removed by filtration, and the filtrate was transferred to a crystallization flask, and 1000 g of acetone was added thereto, and the mixture was stirred and crystallized at about 0 ° C. Filtration gave 18.2 g of Compound (1).
化合物 (I) 的物理性质测定结果: Determination of the physical properties of the compound (I):
UVmax H20nm: 297 UV max H20 nm: 297
IR KBrcm : 1755, 1627, 1393, 1252, 1130 IR KBr cm : 1755, 1627, 1393, 1252, 1130
NMR8 (D20): 1.25 ( 3H, d, J=6.4Hz ) , 1.81-1.96 ( 1Η m) 2.96 (3Η, s) , 3.03 (3Η, s) , 3.14-3.20 (3Η m) , 3.31-3.41 (2Η, m) , 3.62-3.72 ( 1Η m) , 3.90-4.00 ( 1Η, m) , 4.14-4.26 (2Η m) , 4.63 ( 1Η, t, J=8.5Hz) 实施例 3 NMR8 (D 2 0): 1.25 ( 3H, d, J = 6.4 Hz ) , 1.81-1.96 ( 1 Η m) 2.96 (3Η, s) , 3.03 (3Η, s) , 3.14-3.20 (3Η m) , 3.31- 3.41 (2Η, m) , 3.62-3.72 ( 1Η m) , 3.90-4.00 ( 1Η, m) , 4.14-4.26 (2Η m) , 4.63 ( 1Η, t, J=8.5Hz) Example 3
本实施例用来研究从式 (III) 所示化合物制备式 (II) 所示化合物的 反应液的后处理中采用不同处理方法对制备反应的影响。 This example was used to investigate the effect of different treatment methods on the preparation reaction in the post-treatment of the reaction liquid for preparing the compound of the formula (II) from the compound of the formula (III).
采用与实施例 1和实施例 2类似的方法制备式(I)所示化合物, 所不 同的是在中间体式 (Π) 所示化合物后处理中分别采用如下两种方法进行 处理: The compound of the formula (I) was prepared by a method similar to that of Example 1 and Example 2, except that the following two methods were used in the post-treatment of the compound of the intermediate formula (Π):
方法①: 使用水洗一次, 使用食盐水洗涤两次, 然后使用水洗一次; 方法②: 使用磷酸二氢钾 (KH2P04) 水溶液洗涤五次。 Method 1: Wash once with water, twice with saline, and then once with water; Method 2: Wash five times with an aqueous solution of potassium dihydrogen phosphate (KH 2 P0 4 ).
按照上述两种处理方法得到以下结果: According to the above two treatment methods, the following results are obtained:
( 1)使用方法①处理, 处理过程中出现易乳化, 分相难, 需要较长 时间分相; 使用方法②则易分相, 处理反应速度快; (1) It is treated by Method 1. The process is easy to emulsify, the phase separation is difficult, and the phase separation is required for a long time; the use method 2 is easy to phase separation, and the reaction speed is fast;
(2)从液相图谱上看, 在后处理后, 使用方法①处理, 有小的杂质 峰变大的现象, 即杂质明显增加, 容易造成严重药品不良反应; 使用方法 (2) From the liquid phase spectrum, after the post-treatment, using the method 1 treatment, there is a phenomenon that the peak of the small impurity becomes large, that is, the impurity is significantly increased, which is likely to cause serious adverse drug reactions;
②处理则无此现象; 2 treatment does not have this phenomenon;
(3)使用方法①和方法②处理得到的产物产率明显不同。 采用与实施例 1和实施例 2类似的方法制备式(I)所示化合物, 所不 同的是在中间体式 (Π) 所示化合物后处理中分别采用方法①和方法②进 行处理, 按照方法①进行了两批实验, 按照方法②进行了一批实验进行对 比, 结果如表 1。 (3) The yields of the products obtained by the methods 1 and 2 were significantly different. The compound of the formula (I) was prepared by a method similar to that of Example 1 and Example 2, except that the method of the intermediate formula (Π) was used in the post-treatment of the compound (Method 1) and Method 2, respectively. Two batches of experiments were carried out, and a batch of experiments were carried out in accordance with Method 2 for comparison. The results are shown in Table 1.
表 1不同处理方法对产物产率的影响 Table 1 Effect of different treatment methods on product yield
从表 1可以看出使用方法②进行处理, 得到的产物产率明显较高。 结论: 在式 (III) 所示化合物制备式 (II) 所示化合物的反应液中使 用方法②可以使得到的含有式(II) 所示化合物的有机溶液体系较纯, 因 而使式(Π) 所示化合物制备式(I)所示化合物中反应体系在反应完全后 可以通过直接析晶得到产品, 且纯度和收率较高; 而如果在式(III)所示 化合物制备式 (II) 所示化合物的反应液中使用方法②, 即食盐水洗涤, 一方面, 后处理过程中容易出现乳化现象, 会造成产品溶液中式 (II) 所 示化合物收率损失和纯度上的降低; 另一方面, 如果在式 (II) 所示化合 物制备式 (I) 所示化合物中按照本发明的直接析晶法, 得到的式 (I) 所 示化合物的产品纯度会受影响, 因而必须采用繁瑣的后处理方法来得到纯 度较高的产品, 其收率大大降低。 实施例 4 It can be seen from Table 1 that the treatment using Method 2 yields a significantly higher yield. Conclusion: The method 2 for preparing the compound of the formula (II) by using the compound of the formula (III) can be used to make the organic solution system containing the compound of the formula (II) relatively pure, thereby making the formula (Π) The compound shown in the preparation of the compound of the formula (I) can be obtained by direct crystallization after completion of the reaction, and the purity and yield are higher; and if the compound of the formula (III) is used to prepare the formula (II) In the reaction solution of the compound, the method 2 is used, that is, washing with a saline solution. On the one hand, the emulsification phenomenon is likely to occur during the post-treatment, which causes a decrease in the yield loss and purity of the compound represented by the formula (II) in the product solution; If the direct crystallization method according to the present invention is carried out in the preparation of the compound of the formula (I) in the compound of the formula (II), the purity of the product of the compound of the formula (I) obtained is affected, and cumbersome post-treatment must be employed. The method is to obtain a product with higher purity, and the yield thereof is greatly reduced. Example 4
本实施例用来研究在式 (ΙΠ) 所示化合物制备式 (Π) 所示化合物的 反应液的后处理中釆用不同种类的洗涤溶液对产物产量和收率的影响。 This example was used to investigate the effect of different kinds of washing solutions on the product yield and yield in the post-treatment of the reaction solution of the compound of the formula (ΙΠ) prepared by the compound of the formula (ΙΠ).
采用与实施例 1和实施例 2类似的方法制备式(I)所示化合物, 所不 同的是在中间体式 (II) 所示化合物后处理中分别采用表 2所示的溶液进 行洗涤, 结果如表 2所示。 表 2 不同种类的洗涤溶液对产物产量和收率的影响 The compound of the formula (I) was prepared by a method similar to that of Example 1 and Example 2, except that the solution shown in Table 2 was used for the post-treatment of the compound of the formula (II), and the results were as follows. Table 2 shows. Table 2 Effect of different kinds of washing solutions on product yield and yield
由上表 2可知, 在式(III )所示化合物制备式(II )所示化合物的反应 液的后处理中, 选择洗涤溶液非常关键, 不同的洗涤溶液对最终产品的纯 度和收率影响很大, 使用酸性水溶液, 例如磷酸二氢钠或磷酸二氢钾的水 溶液, 与其他各类溶液相比, 可以使得到的式 (Π ) 所示化合物的有机溶 液体系较纯, 大大提高了式(I )所示化合物粗品产量的純度和收率。 由表 2还可以看出, 使用磷酸二氢钾的水溶液作为洗涤溶液效果更好。 实施例 5 It can be seen from the above Table 2 that in the post-treatment of the reaction solution of the compound of the formula (II) to prepare the compound of the formula (II), it is very important to select a washing solution, and different washing solutions have a great influence on the purity and yield of the final product. Large, using an acidic aqueous solution, such as sodium dihydrogen phosphate or potassium dihydrogen phosphate aqueous solution, compared with other types of solutions, can make the organic compound system of the compound of formula (Π) to be purer, greatly improved the formula ( I) The purity and yield of the crude product yield shown. It can also be seen from Table 2 that the use of an aqueous solution of potassium dihydrogen phosphate as a washing solution is more effective. Example 5
本实施例用来研究在式 (III ) 所示化合物制备式 (II ) 所示化合物的 反应液的后处理中采用不同的洗涤温度对产物产量的影响。 This example was conducted to investigate the effect of different washing temperatures on the product yield in the post-treatment of the reaction solution of the compound of the formula (II) in the preparation of the compound of the formula (III).
采用与实施例 1类似的方法制备式 (Π ) 所示化合物, 所不同的是在 后处理中分别采用表 3所示的洗涤温度进行洗涤, 结果如表 3所示。 表 3不同洗涤温度对产物产量的影响 The compound of the formula (?) was prepared in the same manner as in Example 1, except that the washing was carried out by the washing temperature shown in Table 3 in the post-treatment, and the results are shown in Table 3. Table 3 Effect of Different Washing Temperatures on Product Yield
由表 3可知, 在将式(πι)所示化合物与式(IV)所示化合物在减存 在下于有机溶剂中反应生成式(II)所示化合物的反应液中, 使用酸的水 溶液洗涤反应产物并分离出含有式(u)所示化合物的有机溶液层中, 洗 涤温度对式(Π)所示化合物的产量有很大影响, 考虑到最终产量, 洗涤 温度可以为 0°C~40°C, 优选为 20°C〜40°C, 最佳为 34°C。 It can be seen from Table 3 that the reaction solution of the compound of the formula (IV) and the compound of the formula (IV) are reacted in an organic solvent to form a compound of the formula (II), and the reaction solution is washed with an aqueous acid solution. The product is separated into an organic solution layer containing the compound of the formula (u), and the washing temperature has a great influence on the yield of the compound represented by the formula (Π), and the washing temperature may be 0 ° C to 40 ° in consideration of the final yield. C, preferably from 20 ° C to 40 ° C, most preferably 34 ° C.
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/000076 WO2012097471A1 (en) | 2011-01-18 | 2011-01-18 | PREPARATION METHOD OF β-METHYL CARBAPENEM COMPOUND |
| CN2011100424467A CN102603745A (en) | 2011-01-18 | 2011-02-22 | Preparation method of beta-methyl carbapenem compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/000076 WO2012097471A1 (en) | 2011-01-18 | 2011-01-18 | PREPARATION METHOD OF β-METHYL CARBAPENEM COMPOUND |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012097471A1 true WO2012097471A1 (en) | 2012-07-26 |
Family
ID=46515064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2011/000076 Ceased WO2012097471A1 (en) | 2011-01-18 | 2011-01-18 | PREPARATION METHOD OF β-METHYL CARBAPENEM COMPOUND |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012097471A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1948312A (en) * | 2006-03-14 | 2007-04-18 | 深圳市海滨制药有限公司 | Preparation method of meluopeinan |
| CN101410398A (en) * | 2006-03-28 | 2009-04-15 | 株式会社钟化 | Improved process for preparing carbapenem compounds |
| CN101628914A (en) * | 2008-07-15 | 2010-01-20 | 吉尼森实验室有限公司 | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
| CN101935321A (en) * | 2010-07-20 | 2011-01-05 | 深圳市海滨制药有限公司 | Method for synthesizing 1 beta methyl carbapenem antibiotic |
-
2011
- 2011-01-18 WO PCT/CN2011/000076 patent/WO2012097471A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1948312A (en) * | 2006-03-14 | 2007-04-18 | 深圳市海滨制药有限公司 | Preparation method of meluopeinan |
| CN101410398A (en) * | 2006-03-28 | 2009-04-15 | 株式会社钟化 | Improved process for preparing carbapenem compounds |
| CN101628914A (en) * | 2008-07-15 | 2010-01-20 | 吉尼森实验室有限公司 | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
| CN101935321A (en) * | 2010-07-20 | 2011-01-05 | 深圳市海滨制药有限公司 | Method for synthesizing 1 beta methyl carbapenem antibiotic |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101410398B (en) | Improved preparation method of carbapenem compound | |
| US20120095210A1 (en) | Process for the preparation of beta-lactam antibiotic | |
| JP7283861B2 (en) | Carboxamide derivatives in stable crystalline form and their diastereomers | |
| CN106749771A (en) | A kind of easypro more glucose sodium preparation method of high-purity | |
| US9233963B2 (en) | Method for preparing meropenem using zinc powder | |
| IL293066A (en) | Chiral reagents for preparation of homogeneous oligomers | |
| JP5781432B2 (en) | Method for producing pyripyropene derivative | |
| JP4100908B2 (en) | Production method of basic antibiotics and inorganic acid salts and oxalate intermediates | |
| CN107501268A (en) | A kind of preparation method of L-084 and its intermediate | |
| CN100457760C (en) | The preparation method of ertapenem sodium salt | |
| CN102443017B (en) | Preparation method of cefozopran hydrochloride | |
| EP1776365A1 (en) | Meropenem intermediate in crystalline form | |
| WO2012097471A1 (en) | PREPARATION METHOD OF β-METHYL CARBAPENEM COMPOUND | |
| CN1995040A (en) | 4-methyl-7-oxy-1-azabicyclo [3.2.0] hepta-2-olefin-2-carboxylic acid derivative preparation method | |
| KR101774812B1 (en) | Preparation method for tebipenem pivoxil | |
| WO2007116728A1 (en) | Process for production of intermediate for meropenem | |
| CN114105988B (en) | Synthetic method of ertapenem sodium | |
| KR101142757B1 (en) | Process for preparing meropenem trihydrate | |
| CN102532140B (en) | Method for preparing meropenem trihydrate | |
| CN109496215B (en) | A kind of Fosaprepitant phosphate intermediate and preparation method thereof | |
| US20020068829A1 (en) | Process of preparing 3S-3-amino-3-aryl proprionic acid and derivatives thereof | |
| CN102603745A (en) | Preparation method of beta-methyl carbapenem compound | |
| JP2003128674A (en) | NEW PRODUCTION METHOD OF CARBAPENEM ANTIBIOTIC BY OnePot REACTION AND RECRYSTALLIZATION | |
| CN120665002A (en) | Preparation method and application of 3-aminopyrrolidine-1-carboxylic acid tert-butyl ester | |
| CN117659032A (en) | Intermediate of ecteinascidin derivative and synthetic method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11856615 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1301004178 Country of ref document: TH |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11856615 Country of ref document: EP Kind code of ref document: A1 |